Drugs / SIVIFENE
SIVIFENE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00002153 | — | HIV infectious disease, Kaposi's sarcoma, lymphoproliferative syndrome | DEKK-TEC, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00596258 | Nov 2007 → Jul 2008 | cervical intraepithelial neoplasia | Tigris Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00285207 | Jan 2006 → Apr 2008 | cervical intraepithelial neoplasia | Tigris Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIVIFENE | ChEMBL registry synonym — accepted as the source's own label CHEMBL307697 ↗ |
| Known as | 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-hydrazone | “4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-hydrazone (A-007) Topical Gel” NCT00285207 ↗1“4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-Hydrazone (A-007) Topical Gel” NCT00596258 ↗ |
| Known as | A-007 | “A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix” NCT00285207 ↗ |
| Known as | Sivifeno | ChEMBL registry synonym — accepted as the source's own label CHEMBL307697 ↗ |
| Modality | Small molecule | — CHEMBL307697 ↗ |
| Route | Topical | “To evaluate topical A-007” NCT00002153 ↗ |